LUNSUMIO (mosunetuzumab) - Follicular lymphomas (FL)

Reason for request

Clinical Benefit

Insufficient

The Committee deems that the clinical benefit of LUNSUMIO 1 mg and 30 mg (mosunetuzumab), solutions for dilution for infusion, is insufficient, in view of the alternatives, to justify public funding in the MA indication.

Clinical Added Value

Not applicable

-